CuraCell Strengthens Board of Directors with Appointment of Thomas Jaecklin and Martin Forster
Enhancing clinical and strategic expertise to advance next-generation cell therapies
Stockholm, Sweden – CuraCell TX AB (CuraCell) today announced the appointment of Dr. Thomas Jaecklin and Prof. Martin Forster to its Board of Directors, further strengthening the company’s leadership as it advances its mission to develop transformative cell-based therapies.
Dr. Thomas Jaecklin is a drug development leader with over 25 years of experience in academic medicine, biotech and pharma. He played a pivotal role in building Mirum Pharmaceutical success in cholestatic liver disease by initiating the spin-out of its lead assets and leading its clinical development to successful approvals. As Chief Medical Officer of NodThera, he shaped the clinical strategy and financing narrative of the clinical stage biotech active in CV risk reduction, obesity and Parkinson’s Disease.
He has a track record of leading multiple approvals, shaping regulatory policy at the highest level and participated in several financing rounds and company build-ups. Thomas brings deep clinical and operational insight, regulatory acumen and a broad drug development and investor network. Dr. Jaecklin holds an M.D. from the University of Geneva and an M.Sc. from the University of Toronto and is board-certified in paediatrics, neonatology, and critical care medicine.
Prof. Martin Forster is a Professor of Cancer Medicine at University College London (UCL) and Consultant Medical Oncologist at University College London Hospitals NHS Foundation Trust. He specializes in Thoracic and Head and Neck Cancers and has a particular interest in drug development, running a broad portfolio of studies from first-in-human to registration Phase III trials. He has extensive experience in innovative trial design and clinical delivery of studies investigating novel agents and is UCL ECMC Academic Lead and UCLH Clinical Lead for Cancer Research. He collaborates broadly with national and international groups involved in translational research and has published on topics ranging from cancer biology to translational oncology and clinical studies.
“We are delighted to welcome Thomas and Martin to the CuraCell Board,” said Jonas Båtelson, CEO of CuraCell. “Thomas brings exceptional expertise in late-stage drug development and regulatory strategy, while Martin adds deep clinical and translational insight in oncology. Together, their perspectives will be instrumental as we advance our pipeline and expand our impact.”
Dr. Thomas Jaecklin commented:
“CuraCell represents a compelling opportunity at the forefront of cell therapy innovation. I look forward to supporting the company’s continued growth and helping translate its scientific strengths into meaningful value for patients and stakeholders.”
Dr. Martin Forster added:
“CuraCell’s approach to cell-based therapies is both innovative and clinically relevant. I am excited to contribute my experience in oncology drug development and clinical research to support the company’s progress toward delivering new treatment options for patients.”
CuraCell continues to advance its pipeline and partnerships, positioning itself at the forefront of innovation in cell-based therapies.
About CuraCell
CuraCell is a clinical-stage Swedish immunotherapy company pioneering the treatment of cold solid tumours with high unmet need. Using a proprietary process (CytoPLY™), the company extracts, activates and expands T-cells and converts them into potent cytotoxic effector cells with durable anti-tumour activity. Its lead candidate, CC-38, is currently being evaluated in a Phase 1/2a clinical trial.
CuraCell’s R&D facility and headquarters are located at Campus Karolinska in Solna, Sweden, with clinical operations in Frankfurt, Germany. To learn more, visit www.curacell.se and follow CuraCell on LinkedIn.